KNSA - Kiniksa Pharmaceuticals, Ltd.
NASDAQ
->
Healthcare
->
Biotechnology
Hamilton,
Bermuda
Type: Equity
KNSA price evolution
KNSA
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $107.95 | $117.83 | $112.57 | $80.62 |
| Short term investments | $98.42 | $83.26 | $72.42 | $106.88 |
| Net receivables | $21.27 | $3.04 | $24.65 | $7.42 |
| Inventory | $31.12 | $25.58 | $23.96 | $23.43 |
| Total current assets | $276.3 | $256.11 | $246.04 | $231.5 |
| Long term investments | ||||
| Property, plant & equipment | $12.66 | $13.59 | $14.33 | $6.62 |
| Goodwill & intangible assets | $17.25 | $17.5 | $17.75 | $18 |
| Total noncurrent assets | $250.03 | $226.95 | $238.29 | $211.36 |
| Total investments | $98.42 | $83.26 | $72.42 | $106.88 |
| Total assets | $526.32 | $483.06 | $484.33 | $442.86 |
| Current liabilities | ||||
| Accounts payable | $8.25 | $1.01 | $0.65 | $1.39 |
| Deferred revenue | $12.26 | $14.44 | $16.68 | $18.66 |
| Short long term debt | $2.25 | $2.31 | $2.24 | $3.48 |
| Total current liabilities | $63.67 | $53.47 | $47.47 | $36.59 |
| Long term debt | $10.01 | $10.65 | $11.28 | $2.13 |
| Total noncurrent liabilities | $23.82 | $24.47 | $25.2 | $16.18 |
| Total debt | $12.26 | $12.96 | $13.52 | $5.62 |
| Total liabilities | $87.48 | $77.94 | $72.68 | $52.77 |
| Shareholders' equity | ||||
| Retained earnings | -$477.95 | -$503.19 | -$489.33 | -$504.3 |
| Other shareholder equity | $0.01 | -$0 | $0.01 | $0.06 |
| Total shareholder equity | $438.84 | $405.13 | $411.66 | $390.1 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $107.95 | $122.72 | $122.47 | $114.25 |
| Short term investments | $98.42 | $67.89 | $59.73 | $209.44 |
| Net receivables | $21.27 | $20.32 | $3.98 | |
| Inventory | $31.12 | $21.6 | $3.67 | |
| Total current assets | $276.3 | $243.06 | $196.45 | $333.25 |
| Long term investments | ||||
| Property, plant & equipment | $12.66 | $7.04 | $8.38 | $10.62 |
| Goodwill & intangible assets | $17.25 | $18.25 | $19.25 | |
| Total noncurrent assets | $250.03 | $216.61 | $36.35 | $16.21 |
| Total investments | $98.42 | $67.89 | $59.73 | $209.44 |
| Total assets | $526.32 | $459.67 | $232.8 | $349.46 |
| Current liabilities | ||||
| Accounts payable | $8.25 | $7.9 | $1.87 | $0.5 |
| Deferred revenue | $12.26 | $12 | ||
| Short long term debt | $2.25 | $3.3 | $3.38 | $2.11 |
| Total current liabilities | $63.67 | $47.07 | $44.82 | $31.85 |
| Long term debt | $10.01 | $2.62 | $2.67 | $4.88 |
| Total noncurrent liabilities | $23.82 | $16.46 | $2.94 | $5.68 |
| Total debt | $12.26 | $5.92 | $6.05 | $6.99 |
| Total liabilities | $87.48 | $63.52 | $47.76 | $37.53 |
| Shareholders' equity | ||||
| Retained earnings | -$477.95 | -$492.03 | -$675.4 | -$517.47 |
| Other shareholder equity | $0.01 | $0.04 | -$0.07 | -$0.03 |
| Total shareholder equity | $438.84 | $396.15 | $185.04 | $311.94 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $83.39 | $67.05 | $71.47 | $48.34 |
| Cost of revenue | $9.58 | $9.09 | $7.7 | $7.04 |
| Gross Profit | $73.81 | $57.96 | $63.77 | $41.31 |
| Operating activities | ||||
| Research & development | $20.05 | $17.11 | $23.77 | $15.17 |
| Selling, general & administrative | $36.74 | $34.47 | $29.18 | $29.05 |
| Total operating expenses | $73.73 | $68.89 | $66.93 | $52.51 |
| Operating income | $0.08 | -$10.93 | -$3.15 | -$11.2 |
| Income from continuing operations | ||||
| EBIT | $2.45 | -$8.5 | -$1.24 | -$9.36 |
| Income tax expense | -$22.79 | $5.36 | -$16.21 | $2.91 |
| Interest expense | ||||
| Net income | ||||
| Net income | $25.24 | -$13.86 | $14.97 | -$12.27 |
| Income (for common shares) | $25.24 | -$13.86 | $14.97 | -$12.27 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $270.26 | $220.18 | $38.54 | |
| Cost of revenue | $33.41 | $22.89 | $9.1 | |
| Gross Profit | $236.85 | $197.28 | $29.44 | |
| Operating activities | ||||
| Research & development | $76.1 | $65.49 | $99.3 | $112.04 |
| Selling, general & administrative | $129.43 | $97.95 | $85.95 | $45.32 |
| Total operating expenses | $262.05 | $187.51 | $186.08 | $157.36 |
| Operating income | -$25.2 | $9.77 | -$156.64 | -$157.36 |
| Income from continuing operations | ||||
| EBIT | -$16.65 | $11.03 | -$156.54 | -$156.23 |
| Income tax expense | -$30.74 | -$172.34 | $1.39 | $5.15 |
| Interest expense | ||||
| Net income | ||||
| Net income | $14.08 | $183.36 | -$157.92 | -$161.38 |
| Income (for common shares) | $14.08 | $183.36 | -$157.92 | -$161.38 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $25.24 | -$13.86 | $14.97 | -$12.27 |
| Operating activities | ||||
| Depreciation | $1.28 | $1.31 | $1.37 | $1.44 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.77 | $6.79 | $6.47 | $6.12 |
| Total cash flows from operations | $4.33 | $16.99 | -$3.74 | -$4.27 |
| Investing activities | ||||
| Capital expenditures | -$0.06 | -$0.02 | -$0.03 | -$0.02 |
| Investments | -$14.84 | -$12.26 | $35.57 | -$37.9 |
| Total cash flows from investing | -$14.89 | -$12.28 | $35.53 | -$37.92 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.69 | $0.55 | $0.16 | $0.09 |
| Net borrowings | ||||
| Total cash flows from financing | $0.69 | $0.55 | $0.16 | $0.09 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$9.87 | $5.26 | $31.95 | -$42.1 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $14.08 | $183.36 | -$157.92 | -$161.38 |
| Operating activities | ||||
| Depreciation | $5.39 | $5.44 | $4.99 | $3.81 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $27.15 | $25.12 | $25.17 | $20.88 |
| Total cash flows from operations | $13.3 | $5.81 | -$126.3 | -$136.53 |
| Investing activities | ||||
| Capital expenditures | -$0.13 | -$0.01 | -$0.41 | -$0.28 |
| Investments | -$29.43 | -$8.06 | $149.05 | -$23.16 |
| Total cash flows from investing | -$29.56 | -$8.08 | $128.63 | -$23.44 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.5 | $2.52 | $5.88 | $228.22 |
| Net borrowings | ||||
| Total cash flows from financing | $1.5 | $2.52 | $5.88 | $227.09 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$14.76 | $0.24 | $8.22 | $67.11 |
News
Fundamentals
| Market cap | $1.24B |
|---|---|
| Enterprise value | $1.15B |
| Shares outstanding | 70.46M |
| Revenue | $270.26M |
|---|---|
| EBITDA | -$11.26M |
| EBIT | -$16.65M |
| Net Income | $14.08M |
| Revenue Q/Q | 34.76% |
| Revenue Y/Y | 22.74% |
| P/E ratio | 88.10 |
|---|---|
| EV/Sales | 4.24 |
| EV/EBITDA | -101.72 |
| EV/EBIT | -68.77 |
| P/S ratio | 4.59 |
| P/B ratio | 2.83 |
| Book/Share | 6.23 |
| Cash/Share | 1.53 |
| EPS | $0.20 |
|---|---|
| ROA | 2.91% |
| ROE | 3.42% |
| Debt/Equity | 0.20 |
|---|---|
| Net debt/EBITDA | 1.82 |
| Current ratio | 4.34 |
| Quick ratio | 3.85 |